You are here

Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
University of Alabama at Birmingham
Birmingham, Alabama, 35233 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Onychomycosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Witnessed, signed informed consent approved by Institutional Review Board/Ethics
Committee

- A signed Health Insurance Portability and Accountability Act (HIPAA) authorization
form which permits the use and disclosure of subject's individually identifiable
health information for those enrolled in the United States of America

- Male or female subjects of any race 18 -65 years of age

- Subjects with a diagnosis of onychomycosis of at least one great toenail and with a
positive KOH wet mount and a positive fungal culture for dermatophyte species

- Onychomycosis involving 20-60% of the affected great toenail as determined at baseline
(Day1) by visual inspection after the nail has been trimmed

- The combined thickness of the distal nail plate and the associated hyperkeratotic nail
bed

- Affected great toenail to be treated is capable of re-growth as documented by history
or recent observation of at least 2 mm of growth

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Females of childbearing potential not using a highly effective method of birth control
(e.g. implants, injectables, combined oral contraceptives, some intrauterine
contraceptive devices) during the study

- Subjects unwilling to refrain from the use of nail cosmetics such as clear and or
colored nail lacquers from the screening visit until the end of the study

- Subjects with chronic moccasin type of T. pedis

- Subjects with a history of having failed any previous topical antifungal therapy for
their onychomycosis

- Diabetes mellitus requiring treatment other than diet and exercise

- Subjects that have not undergone the specified washout period(s) for the following
topical preparations or subjects who require the concurrent use of any of the
following topical medications:

1. Topical antifungal applied to toenails (does not include antifungals for
treatment of T. pedis): 12 weeks

2. Anti-inflammatories, corticosteroids, topical immunomodulators (in the treatment
area): 2 weeks

- Subjects that have not undergone the specified washout period(s) for the following
systemic medications or subjects who require the concurrent use of any of the
following systemic medications:

1. Corticosteroids (including intramuscular injections): 2 weeks

2. Antifungals for treatment of onychomycosis or any systemic antifungal with known
activity against dermatophyte species: 24 weeks

3. Systemic immunomodulators: 4 weeks

- Treatment of any type for cancer within the last 6 months

- History of any significant internal disease

- Subjects with a medical history of current or past psoriasis of the skin and/or nails

- Concurrent lichen planus

- Subjects who are known to be allergic to any of the test product(s) or any components
in the test product(s) or history of hypersensitivity or allergic reactions to any of
the study preparations as described in the Investigator's Brochure

- Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary
disorders, onychogryphosis, trauma to the nail(s) to be treated

- AIDS or AIDS related complex

- History of street drug or alcohol abuse

- Any subject not able to meet the study attendance requirements

- Subjects who have participated in any other trial of an investigational drug or device
within 60 days prior to enrollment or participation in a research study concurrent
with this study

NCT00680134
Pfizer
Completed
Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Onychomycosis of Toenails
NCT01270971
All Genders
18+
Years
Multiple Sites
Onychomycosis
NCT00680095
All Genders
18+
Years
Lynchburg, Virginia
Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis
An Open Label, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 1% and 5% Solutions for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail
The purpose of the study is to determine the safety and efficacy of 1% and 5% AN2690 solutions in the treatment of distal, subungual onychomycosis of the great toenail.
The first group of 30 protocol-qualified subjects will be assigned to Treatment Group 1 and given 1% AN2690 Solution. The second group of 30 protocol-qualified subjects will be assigned to Treatment Group 2 and given 5% AN2690 Solution.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Onychomycosis
  • Drug: AN2690
    AN2690 1% Solution, once daily for 180 days
  • Drug: AN2690
    AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
  • Experimental: Group/Cohort 1
    AN2690 1% Solution (30 subjects)
    Intervention: Drug: AN2690
  • Experimental: Group/Cohort 2
    AN2690 5% Solution (30 subjects)
    Intervention: Drug: AN2690
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
August 2007
August 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Witnessed, signed informed consent approved by Institutional Review Board/Ethics Committee
  • A signed Health Insurance Portability and Accountability Act (HIPAA) authorization form which permits the use and disclosure of subject's individually identifiable health information for those enrolled in the United States of America
  • Male or female subjects of any race 18 -65 years of age
  • Subjects with a diagnosis of onychomycosis of at least one great toenail and with a positive KOH wet mount and a positive fungal culture for dermatophyte species
  • Onychomycosis involving 20-60% of the affected great toenail as determined at baseline (Day1) by visual inspection after the nail has been trimmed
  • The combined thickness of the distal nail plate and the associated hyperkeratotic nail bed <3 mm
  • Affected great toenail to be treated is capable of re-growth as documented by history or recent observation of at least 2 mm of growth

Exclusion Criteria:

  • Females of childbearing potential not using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices) during the study
  • Subjects unwilling to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study
  • Subjects with chronic moccasin type of T. pedis
  • Subjects with a history of having failed any previous topical antifungal therapy for their onychomycosis
  • Diabetes mellitus requiring treatment other than diet and exercise
  • Subjects that have not undergone the specified washout period(s) for the following topical preparations or subjects who require the concurrent use of any of the following topical medications:

    1. Topical antifungal applied to toenails (does not include antifungals for treatment of T. pedis): 12 weeks
    2. Anti-inflammatories, corticosteroids, topical immunomodulators (in the treatment area): 2 weeks
  • Subjects that have not undergone the specified washout period(s) for the following systemic medications or subjects who require the concurrent use of any of the following systemic medications:

    1. Corticosteroids (including intramuscular injections): 2 weeks
    2. Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophyte species: 24 weeks
    3. Systemic immunomodulators: 4 weeks
  • Treatment of any type for cancer within the last 6 months
  • History of any significant internal disease
  • Subjects with a medical history of current or past psoriasis of the skin and/or nails
  • Concurrent lichen planus
  • Subjects who are known to be allergic to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure
  • Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated
  • AIDS or AIDS related complex
  • History of street drug or alcohol abuse
  • Any subject not able to meet the study attendance requirements
  • Subjects who have participated in any other trial of an investigational drug or device within 60 days prior to enrollment or participation in a research study concurrent with this study
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00680134
AN2690-ONYC-203
No
Not Provided
Not Provided
Karl Beutner, M.D., Ph.D., Chief Medical Officer, Anacor Pharmaceuticals, Inc.
Pfizer
Not Provided
Study Director: Karl Beutner, MD, PhD Pfizer
Pfizer
May 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now